期刊文献+

MicroRNA-100对肝癌细胞增殖活力和细胞周期的影响 被引量:11

Effect of microRNA-100 on proliferation activity and cell cycle of hepatocarcinoma cells
下载PDF
导出
摘要 目的:探讨microRNA-100(miR-100)对肝癌细胞增殖活力和细胞周期的影响及其可能机制。方法:通过脂质体介导将人工合成的miR-100模拟物及其阴性对照转染人肝癌HepG2细胞,用细胞计数试剂盒8(CCK-8)方法检测转染后HepG2细胞的增殖活力,用流式细胞术判定细胞周期分布,并进一步用实时荧光定量RT-PCR和Western blotting分析Polo样激酶1(Plk1)的表达水平。结果:荧光显微镜下观察到经阳离子脂质体介导的细胞转染效率大于85%。转染miR-100模拟物的实验组细胞的增殖抑制率在24、48和72 h分别为(43.5±12.2)%、(46.5±3.7)%和(52.1±0.2)%,均显著高于对照组细胞(P<0.01),并且在72 h实验组细胞增殖指数(35.8±1.4)低于阴性对照组(39.2±1.0)和单纯脂质体组(40.7±2.0)(P<0.05)。同时与对照组相比,实验组细胞Plk1 mRNA和蛋白表达水平在转染miR-100后72 h明显降低(P<0.05)。结论:miR-100可抑制肝癌细胞增殖,其机制可能与其下调Plk1的表达有关。 AIM: To investigate the effect of microRNA-100 (miR-100) on the proliferation activity and cell cycle of hepatocarcinoma cells. METHODS : Synthetic miR-100 mimic and its negative control were transfected into hu- man hepatocarcinoma HepG2 cells by liposome method. After transfection, the cell counting kit-8 (CCK-8) was used to measure the cell proliferation activity. The cell cycle distribution was determined by flow cytometry. The expression of Polo- like kinase 1 (Plkl) at mRNA and protein levels was detected by quantitative real-time PCR (qRT-PCR) and Western blotting. RESULTS: The transfection efficiency mediated by cationic liposome was greater than 85%. The inhibitory rates of cell proliferation in HepG2 cells were (43.5 ± 12.2) %, (46.5 ± 3.7 ) % and (52.1 ± 0.2) % at 24 h, 48 h and 72 h after transfected with miR-100 mimic, respectively, which were significantly increased as compared with the control cells. Moreover, the cell proliferation index in experimental group (35.8 ± 1.4) was higher than that in negative control group (39.2 ± 1.0) and simple liposome group (40.7 ± 2.0) at 72 h. At the same time, the mRNA and protein expression levels of Plkl obviously decreased in HepG2 cells transfected with miR-100 at 72 h after transfection. CONCLUSION: miR-100 suppresses the proliferation activity of hepatocarcinoma cells by down-regulating Plkl gene expression.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2013年第1期108-111,共4页 Chinese Journal of Pathophysiology
基金 河南省杰出青年科学基金资助项目(No.0512000800)
关键词 肝肿瘤 MicroRNA-100 POLO样激酶1 Liver neoplasms MicroRNA-100 Polo-like kinase 1
  • 相关文献

参考文献12

  • 1Shi W, Alajez NM, Bastianutto C, et al. Significance of Plkl regulation by miR-100 in human nasopharyngeal cancer [J]. Int J Cancer, 2010, 126(9):2036-2048.
  • 2Peng DX, Luo M, Qiu LW, et al. Prognostic implications of microRNA-100 and its functional roles in human epithe- lial ovarian cancer[J]. Oncol Rep, 2012, 27(4) :1238- 1244.
  • 3Li BH, Zhou JS, Ye F,et al. Reduced miR-100 expres- sion in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein [J].Eur J Cancer, 2011,47(14) :2166-2174.
  • 4余桂芳,严跃红,王瑞鑫,曾文铤,朱科伦.不同缺氧状态对人肝癌HepG2细胞侵袭和转移能力的影响[J].中国病理生理杂志,2012,28(2):281-286. 被引量:10
  • 5黎建军,陈诗萍,古模发,杨炜敏,李永强,王其京,何佳,潘科,赵靖靖,夏建川.NK细胞对不同人肝癌细胞株的杀伤作用[J].中国病理生理杂志,2012,28(4):638-642. 被引量:12
  • 6Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA pro- filing in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations [ J ]. Hepatology, 2008, 47 (6) : 1955-1963.
  • 7许林锋,倪嘉延,陈耀庭,孙宏亮,吴裕丹.HIF-1α基因沉默对大鼠肝癌CBRH-7919细胞p27和Ki67表达的影响[J].中国病理生理杂志,2012,28(10):1825-1829. 被引量:13
  • 8Li Q, Wang G, Shan JL, et al. MicroRNA-224 is upregu- lated in HepG2 cells and involved in cellular migration and invasion [ J]. J Gastroenterol Hepatol, 2010, 25 ( 1 ) : 164-171.
  • 9Strebhardt K. Multifaceted Polo-like kinases: drug targets and antitargets for can-cer therapy [ J ]. Nat Rev Drug Discov, 2010, 9 ( 8 ) : 643-660.
  • 10Grinshtein N, Datti A, Fujitani M, et al. Small molecule kinase inhibitor screen identifies Polo-like kinase 1 as a target for neuroblastoma tumor-initiating ceils [ J ]. Cancer Res, 2011, 71(4) :1385-1395.

二级参考文献32

  • 1Llovet JM,Burroughs A,Bruix J.Hepatocellular carcino-ma[J].Lancet,2003,362(9399):1907-1917.
  • 2Yoo HY,Patt CH,Geschwind JF,et al.The outcome of liver transplantation in patients with hepatocellular carcino-ma in the United States between1988and2001:5-year survival has improved significantly with time[J].J Clin Oncol,2003,21(23):4329-4335.
  • 3Allgaier HP,Deibert P,Olschewski M,et al.Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center a-nalysis including132patients[J].Int J Cancer,1998,79(6):601–605.
  • 4Takayasu K,Wakao F,Moriyama N,et al.Postresection recurrence of hepatocellular carcinoma treated by arterial embolization:analysis of prognostic factors[J]Hepatolo-gy,1992,16(4):906-911.
  • 5Farag SS,VanDeusen JB,Fehniger TA,et al.Biology and clinical impact of human natural killer cells[J].Int J Hematol,2003,78(1):7-17.
  • 6Wada Y,Nakashima O,Kutami R,et al.Clinicopatho-logical study on hepatocellular carcinoma with lymphocytic infiltration[J].Hepatology,1998,27(2):407-414.
  • 7Cai L,Zhang Z,Zhou L,et al.Functional impairment in circulating and intrahepatic NK cells and relative mecha-nism in hepatocellular carcinoma patients[J].Clin Immu-nol,2008,129(3):428-437.
  • 8Korangy F,Hchst B,Manns MP,et al.Immune respon-ses in hepatocellular carcinoma[J].Dig Dis,2010,28(1):150-154.
  • 9Miyagi T,Takehara T,Tatsumi T,et al.CD1d-media-ted stimulation of natural killer T cells selectively activates hepatic naturalkiller cells to eliminate experimentally dis-seminated hepatoma cells in murine liver[J].Int J Canc-er,2003,106(1):81-89.
  • 10Taketomi A,Shimada M,Shirabe K,et al.Natural killer cell activity in patients with hepatocellular carcinoma:a new prognostic indicator after hepatectomy[J].Cancer,1998,83(1):58-63.

共引文献29

同被引文献115

  • 1李琼,王阁,王红中,杨志祥,单锦露,陈川,张志敏,许文,王东,李增鹏.MicroRNA在HepG_2肝癌细胞表达差异谱的研究[J].重庆医学,2007,36(20):2024-2025. 被引量:8
  • 2Eckstein F. Small non-coding RNAs asmagic bullets [ J ]. Trends Biochem Sci, 2005, 30 (8): 445-452.
  • 3Wu W, Sun M, Zou GM, et al. MicroRNA and cancer: current status and prospective [ J ]. Int J Cancer, 2007, 120(5 ) :953-960.
  • 4Petri A, Lindow M, Kauppinen S. MicroRNA silencing in primates: towards development of novel therapeutics [ J ]. Cancer Res, 2009, 69(2) :393-395.
  • 5Wang H, Li M, Zhang R, et al. Effect of miR-335 upreg- ulation on the apoptosls and invasion of lung cancer cell A549 and H1299[J], Tumour Biol, 2013 Jun 6. [Epub ahead of print].
  • 6Xu Y, Zhao F, Wang Z, et al. MieroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bel-w and speeifieity protein 1 [ J ]. Oncogene, 2012, 31 ( 11 ) : 1398-1407.
  • 7Heyn H, Engelmarm M, Sehreek S, et al. MieroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development[J]. Int J Cancer, 2011, 129 (12) :2797-2806.
  • 8Maire G, Martin JW, Yoshimoto M, et al. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of mieroRNA deregulation in osteosarcoma [J]. Cancer Genet, 2011,204(3) :138-146.
  • 9Hu H, Zhang Y, Cai XH, et al. Changes in microRNA ex- pression in the MG-63 osteosarcoma cell line compared with osteoblasts[J]. Oncol Lett, 2012,4(5) :1037-1042.
  • 10Shu M, Zheng X, Wu S, et al. Targeting oncogenic miR- 335 inhibits grouth and invasion of malignant astrocytoma cells[J]. Mol Cancer, 2011,10:59.

引证文献11

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部